Research programme: T-cell therapies - Apollo Therapeutics
Latest Information Update: 09 Mar 2017
At a glance
- Originator Imperial College of Science, Technology and Medicine; University College London; University of Cambridge
- Developer Apollo Therapeutics; University of Cambridge
- Mechanism of Action Cell replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders; Cancer; Infections